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PORTAL VEIN THROMBOSIS AND LIVER 
TRANSPLANTATION 
Our attention has been drawn to the June 1992 
issue of HOSPITAL PHYSICIAN, particularly the 
section on Board Review in Internal Medicine.1 
reconstruction for various associated occlusive and 
hypoplastic abnormalities in patients undergoing 
OLTX. Despite these successes, refinement in 
technique continues as demonstrated by Tzakis et al5 
using the venous jump grafts in PVT in 1989. Fur-
thermore, just recently, Stieber et al6 in 1991, 
expanded the work on the spectrum of PVr in liver 
transplantation replete with graphic details on the sev-
eral techniques currently used to ensure successful 
revascularization in patients with PVT undergoing 
OLTX. 
On the issue of portal vein thrombosis (PVT) in 
orthotopic liver transplantation (OLTX), we wish to 
bring to your attention, the response to question 15: 
"Of the following, which represents the most impor-
tant contraindication to liver transplantation?" The 
answer was Portal Vein Thrombosis (D); and the sub-
sequent explanation, "Portal vein thrombosis tech-
nically precludes successful liver transplantation." 
In 1992, PVf by itself, is not a contraindication to 
OLTX. Rapid advances in liver transplantation over 
the years, particularly the last decade, have led to the 
identification and successful resolution of several 
problems that had previously contraindicated or 
made liver transplantation a hazardous enterprise.2 
Without question, the problem of PVT was a difficult 
one in OLTX. However, by 1985, Shaw et al3 had 
reported on the successful reconstruction of the 
portal vein in two patients with PVT undergoing 
OLTX. Later in 1986, Lerut et al 4 published the 
University of Pittsburgh experience (from 1980 to 
1984) at not only portal vein but also vena cava 
As these developments unfolded, Maddrey and 
Van Thiel7 as far back as 1988 indicated that several 
problems (PVT being one of them) that had 
originally been listed as contraindications to liver 
transplantation were no longer so. 
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Taken together, therefore, we are of the opinion 
that from our experience and from a review of the 
literature, PVT by itself no longer constitutes a 
contraindication to liver transplantation. 
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EDITOR'S NOTE: 
The author of the original article concurs with the 
condusions of Odocha et aL 
ICE WATER: NOT THE ANSWER TO HEAT STROKE 
I was intrigued to read the article in the September 
1992 issue on heatstroke (Ukiwe J. Heat stroke. 
Hospital Physician. 1992;28:4649.). The author recom-
mended using icepacks rubbed on the body to get the 
temperature below 101°F. He is aware that ice water 
and similarly cold substances will induce vasocon-
striction, thereby making the job of heat dissipation 
harder. 
Saudi Arabia, the site of the Annual HAlJ, is 
frequently faced with the problem of older and 
otherwise unacclimatized individuals descending en 
masse for weeks at a time. They have tried a variety of 
treatments for this condition and found that the most 
effective was placing the patient in a temperate room 
and exposing them to a strong ventilating system. I 
cannot cite you the appropriate references, but this 
was a topic discussed in our tropical medicine journal 
club about two years ago. 
Robert Wmsball, MD, MPH 
Richmond, Calif. 
TORADOL INfORMATION CLARIFIED 
In your September 1992 issue [Rx Update. Hospital 
Physician, 1992;28(9):52], information about Toradol 
(ketorolac tromethamine), the nonsteroidal anti-
inflammatory drug (NSAID) marketed by Syntex 
Laboratories and Roche Laboratories, was discussed. 
We would like to clarify the information presented 
regarding the safety of using ketorolac for periods 
beyond 5 days. Although both intramuscular (1M) 
and oral ketorolac are indicated in the management 
of pain, the recommended duration of use is different 
for the two forms of ketorolac. ToradolIM is indicated 
for the short-term management of pain for up to 5 
days. Safety studies of 1M ketorolac have not been 
conducted beyond 5 days. The use of ToradolORAL 
is, however, not restricted to 5 days. Oral ketorolac is 
indicated for limited duration use, as needed in the 
management of pain. 
Ketorolac shares the risks associated with other 
NSAIDs when taken chronically, including the 
potential to cause gastrointestinal (GI) bleeding, 
ulceration, and perforation. As with other NSAlDs, 
ketorolac should be used with caution in patients with 
a prior history of serious GI events, and patients with 
other risk factors known to be associated with peptic 
ulcer disease (particularly elderly patients); patients 
with impaired renal or hepatic function, or a history 
of kidney or liver disease; patients with coagulation 
disorders, and patients receiving drug therapy that 
interferes with hemostasis. It should also be noted 
that ketorolac is contraindicated in patients with 
previously demonstrated hypersensitivity to ketorolac, 
or in those with the complete or partial syndrome of 
nasal polyps, angioedema, and bronchospastic 
reactivity (eg, asthma) or other allergic manifestations 
to aspirin or other NSAIDs. The Toradol package 
insert should be consulted for full prescribing 
information. 
Ronald H. Lewis, MD 
Senior Associate Medical Director 
Medical Services Department 
Syntex Laboratories, Inc 
Palo Alto, Calif. 
Hospital Physician welcomes your comments 
on these and other important medical issues. 
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